GlobeNewswire 8/17/2016 MorphoSys AG: Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) with the a...
GlobeNewswire 8/9/2016 MorphoSys AG: Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) with the a...
GlobeNewswire 8/3/2016 MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients wit...
GlobeNewswire 8/1/2016 MorphoSys AG Reports Results for the First Six Months of 2016
GlobeNewswire 7/25/2016 MorphoSys to Host Q2 2016 Conference Call on August 1, 2016
GlobeNewswire 7/4/2016 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with No...
GlobeNewswire 6/17/2016 MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long...
GlobeNewswire 6/14/2016 MorphoSys AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) with the ...
GlobeNewswire 6/9/2016 Director's Dealings announcement according to §15a WpHG (the German Securities Trading Act)
GlobeNewswire 6/6/2016 MorphoSys Presents Updated Clinical Data for MOR202 in Multiple Myeloma and for MOR208 in Non-Hodgki...
GlobeNewswire 6/3/2016 MorphoSys AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) with the ...
GlobeNewswire 6/2/2016 MorphoSys AG Reports Outcome of Annual General Meeting 2016
GlobeNewswire 6/1/2016 MorphoSys to Present at Six Upcoming Conferences
GlobeNewswire 5/24/2016 MorphoSys and MD Anderson Cancer Center Join Forces for the Development of Novel Oncology Therapeuti...
GlobeNewswire 5/19/2016 MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming ASCO Annual Meeting 201...
GlobeNewswire 5/17/2016 Director's Dealings announcement according to §15a WpHG (the German Securities Trading Act)
GlobeNewswire 5/17/2016 Director's Dealings announcement according to §15a WpHG (the German Securities Trading Act)
GlobeNewswire 5/4/2016 MorphoSys to Present at Three Upcoming Conferences
GlobeNewswire 5/3/2016 MorphoSys AG Reports Results for the First Three Months of 2016
GlobeNewswire 4/27/2016 MorphoSys to Host Q1 2016 Conference Call on May 3, 2016
GlobeNewswire 4/21/2016 MorphoSys AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bim...
GlobeNewswire 4/21/2016 Ad hoc: MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab
GlobeNewswire 4/20/2016 MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on June 2, 2016 according t...
GlobeNewswire 4/18/2016 MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis
GlobeNewswire 4/7/2016 Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106